Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mesoblast Limited ( (AU:MSB) ) just unveiled an update.
Mesoblast will host its inaugural R&D Day in New York on April 8, 2026, featuring its senior leadership and external experts in a live webcast for investors and stakeholders. The event aims to showcase corporate strategy, the commercialization trajectory of flagship product Ryoncil, and the breadth of its pipeline in inflammatory pain and cardiovascular disease.
Management plans to highlight key upcoming milestones and introduce new technology intended to power the next generation of cellular medicines, signaling a push to reinforce the company’s leadership in allogeneic cell therapies. By spotlighting growth drivers, pipeline depth and innovation capabilities, the event is positioned to strengthen investor confidence and clarify Mesoblast’s competitive stance in the rapidly evolving cell therapy market.
The most recent analyst rating on (AU:MSB) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is a biotechnology company specializing in allogeneic, off-the-shelf cellular medicines targeting severe and life-threatening inflammatory conditions. Built on proprietary mesenchymal lineage cell therapy platforms, its lead product Ryoncil is the first FDA-approved mesenchymal stromal cell therapy and is partnered for commercialization across Japan, Europe and China.
The company is advancing additional indications for Ryoncil, including adult steroid-refractory acute graft versus host disease and biologic-resistant inflammatory bowel disease, while its rexlemestrocel-L platform targets heart failure and chronic low back pain. Mesoblast’s extensive global intellectual property estate and industrial-scale manufacturing underpin its ambition to supply cryopreserved cellular therapies worldwide from bases in Australia, the United States and Singapore.
Average Trading Volume: 4,064,570
Technical Sentiment Signal: Hold
Current Market Cap: A$2.64B
For a thorough assessment of MSB stock, go to TipRanks’ Stock Analysis page.